OKYO Pharma Limited (OKYO)

Market Cap	87.33M +127.7%
Revenue (ttm)	n/a
Net Income	-4.61M
EPS	-0.11
Shares Out	51.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	259,556
Open	1.820
Previous Close	1.760
Day's Range	1.695 - 1.850
52-Week Range	1.030 - 3.349
Beta	-0.23
Analysts	Strong Buy
Price Target	6.33 (+263.79%)
Earnings Date	Jul 18, 2025

About OKYO

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited wa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 2022
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: OKYO
• Website: https://okyopharma.com

Analyst Summary

According to 3 analysts, the average rating for OKYO stock is "Strong Buy." The 12-month stock price target is $6.33, which is an increase of 263.79% from the latest price.

Price Target

$6.33

(263.79% upside)

Analyst Consensus: Strong Buy